Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies

Journal of Clinical Gastroenterology

Volumn 45, Issue 9, 2011, Pages 790-793

  Basseri, Robert J ^a   Kunkel, David ^a   Low, Kimberly ^a   Conklin, Jeffrey L ^a   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

constipation; diarrhea; IBS

Indexed keywords

ADULT; AGED; ARTICLE; BRISTOL STOOL SCALE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80052935331     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182053cea     Document Type: Article

References (17)

1. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2:653-654. (Pubitemid 9004104)
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
3. Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004; 54:495-502. (Pubitemid 38931344)
4. Gwee KA, Wee S, Wong ML, et al. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol. 2004;99:924-931. (Pubitemid 39090225)
5. Drossman DA, Richter JE, Talley NJ, et al, eds. Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. Boston: Little, Brown; 1994.
6. Drossman DA, Corazziari E, Talley NJ et al. Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment. A Multinational Consensus. Lawrence, KS: Allen Press; 2000.
7. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15: 1655-1666. (Pubitemid 32912410)
8. Novick J, Miner P, Krause R, et al. A randomized, doubleblind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
9. Drossman DA, Toner BB, Whitehead WE, et al. Cognitivebehavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31. (Pubitemid 36799103)
10. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14:23-34. (Pubitemid 30058157)
11. Ersryd A, Posserud I, Abrahamsson H, et al. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007;26:953-961. (Pubitemid 47346699)
12. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563. (Pubitemid 46780934)
13. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-924. (Pubitemid 27382038)
14. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing and Health. 1990;13:227-236.
15. Norman G. Likert scales, levels of measurement and the "laws" of statistics. Adv Health Sci Educ Theory Pract. 2010. [Epub ahead of print].
16. Rome Foundation. Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:301-312.
17. Guidance for Industry. Irritable bowel syndrome: clinical evaluation of products for treatment. FDA Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER); March 2010.